Does social media bring commercial benefits to GSK? That's not exactly the point, according to Quayle and Morgan. "Increasing sales is not one of our KPIs", says Morgan, "although building ...

The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.

“We really became impressed with what IDRx had achieved,” GSK Chief Commercial Officer Luke Miels told Fierce Biotech in an interview ahead of the J.P. Morgan Healthcare Conference.

chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised a $120 million Series B financing led by RA Capital Management, Commodore Capital and Blackstone ...

The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of £38billion.

He added that GSK's "global clinical development capability and strong commercial presence in oncology will help to accelerate the development of this novel medicine".

Luke Miels, GSK’s chief commercial officer, said: “This acquisition is consistent with our approach of acquiring assets that address validated targets and where there is clear unmet medical ...

Luke Miels, Chief Commercial Officer, GSK, said: "IDRX-42 complements our growing portfolio in gastrointestinal cancers. This acquisition is consistent with our approach of acquiring assets that ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six ...

Geneos Wealth Management Inc. purchased a new stake in shares of GSK plc (NYSE:GSK – Free Report) during the fourth quarter, ...